citic securities·2026-03-24 05:56Investment Rating - The report maintains a positive outlook on WuXi AppTec, indicating a strong growth trajectory and a valuation reset [4]. Core Insights - WuXi AppTec's Q4 2025 performance aligns with earnings forecasts, with total revenue growth projected at 13-17% and sustainable business revenue growth at 18-22% for 2026, despite geopolitical uncertainties [4]. - The company has shown robust order momentum, with new orders in Q4 2025 increasing by 29% year-over-year, and TIDES orders accelerating from 17% to 20% growth [4][5]. - The recent stock price pullback is viewed as an opportunity for investment, as the increasing share of CMO (Contract Manufacturing Organization) business reduces sensitivity to interest rate changes and biotech financing [5]. Summary by Sections Company Overview - WuXi AppTec operates globally across Asia, Europe, and North America, providing comprehensive R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire R&D cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular diagnostics and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Growth Drivers - The overall order growth rate of 29% in Q4 2025 surpasses the TIDES order growth rate of 20%, suggesting a more balanced growth driver for 2026-27 [7]. - The number of CMO projects is expected to increase from 72 in Q4 2024 to 83 in Q4 2025, maintaining global competitiveness despite local supply chain trends [6]. Catalysts - Recent stock price fluctuations have enhanced valuation attractiveness, creating favorable investment opportunities [8].